Merrimack Announces Timing of Fourth Quarter 2015 Investor Conference Call

Feb 17, 2016, 08:00 ET from Merrimack Pharmaceuticals, Inc.

CAMBRIDGE, Mass., Feb. 17, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK)  today announced that the company will host its Fourth Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Thursday, February 25.

The call will cover an update on Merrimack's progress as well as a summary of fourth quarter and full year 2015 financials. A press release detailing the information to be discussed on the call will be issued the afternoon of Thursday, February 25. Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 43765613.

A listen-only webcast of the call will be available in the Investors section of Merrimack's website,, and a replay of the call will be archived there for six weeks.

About Merrimack

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDE® (irinotecan liposome injection), was approved by the U.S. FDA on October 22, 2015.With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. For more information, please visit Merrimack's website at or connect on Twitter at @MerrimackPharma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.


Investor Contact: Geoffrey M. Grande, CFA 617-441-7602

Media Contact: Marianne McMorrow 774-776-1478


SOURCE Merrimack Pharmaceuticals, Inc.